- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Pharmaceutical Technology-12-02-2012
Pharmaceutical Technology
Pharmaceutical Technology, December 2012 Issue (PDF)
December 02, 2012
Issue PDF
36
12
Job Security - Annual Employment Survey Results Show Increased Confidence
Tracking the Supply Chain
December 02, 2012
Special Features
36
12
As the battle against counterfeits gains momentum, PharmTech speaks to Mark Davison, CEO of Blue Sphere Health, and Craig Stobie, global life sciences sector manager at Domino Printing Sciences, about the challenges involved.
Harmonizing Global Efforts Against Counterfeits
December 02, 2012
Special Features
36
12
In addition to globalisation, high financial rewards and low penalties for counterfeiters are contributing to the rise in fake medicines.
Harnessing the Power of Fingerprinting Technologies
December 02, 2012
Special Features
36
12
A few years ago, drug criminals would put all their efforts into matching packaging and labeling, or manufacturing good-looking fake materials. Today, criminals are capable of much more.
Mice on a Mission
December 02, 2012
Agent-in Place
36
12
To ensure the accuracy of scientific testing, protect the subjects to avoid data contamination.
When Disaster Strikes at Home
December 02, 2012
From The Editor
36
12
PDA's strategic plan calls for maintaining valuable and effective relationships with global regulators.
Acquisitions Reshape the Bio/Pharm Services Industry
December 02, 2012
Outsourcing Outlook
36
12
The quest to build critical mass and broaden capabilities has been a key factor in deal-making.
Development and Commercialization of a Novel Modified Release Tablet Technology
December 02, 2012
Peer-Reviewed Research
36
12
GlaxoSmithKline recently developed a novel technology for the formulation of modified-release tablets. The authors describe the route from development to commercialization.
Health Policy Challenges for Obama Administration
December 02, 2012
Regulatory Watch
36
12
White House and Congress likely to struggle over funding for bio/pharmaceutical regulation.
Job Security
December 02, 2012
Special Report
36
12
Annual employment survey results show greater confidence in the pharma industry.
Innovation in a Leading Disease Target: Alzheimer's
December 02, 2012
Special Features
36
12
An interview with Eric M. Parker, Ph.D., Executive Director and Neuroscience Site Lead, Merck Research Laboratories, about the Merck BACE team's winning research.
Patents and Postapproval Batch Testing
December 02, 2012
Viewpoint
36
12
Can postapproval FDA filings immunize pharma companies from patent lawsuits?
Pharma Innovation
December 02, 2012
Special Features
36
12
A look at the year's leaders in innovation strategy, including the top bio/pharmaceutical companies and award recipients from AAPS, PhRMA, and CPhI.
Collaborating to Protect the Supply Chain from Counterfeiters
December 02, 2012
Special Features
36
12
Adeline Siew PharmTech speaks to Lynne Byers and Brian Johnson about Rx-360's initiatives to protect patient safety.
Time to Revise ICH Q9
December 02, 2012
Statistical Solutions
36
12
A change in terminology could emphasize patient protection.
In the Spotlight December 2012
December 02, 2012
In the Spotlight
36
12
New product reviews for December 2012.
Q&A with Richard Shor, President of SaniSure
December 02, 2012
36
12
Q&A with Richard Shor, President of SaniSure.
Report from South Korea
December 02, 2012
In the Field
36
12
Domestic companies are changing their business models in response to recent drug price cuts.
The Class of 2012 for New Molecular Entities and Biologics
December 02, 2012
Pharma Ingredients
36
12
As 2012 comes to a close, Pfizer leads among Big Pharma companies for FDA approvals of new molecular entities and biologics.
A Lifecycle Approach to Optimizing Cleaning Systems
December 02, 2012
Troubleshooting
36
12
Clean-in-place systems should be optimized during design and commissioning and after validation.